Evidence map›Paper›PMID 41837178›Full record

ArticleNAR cancer2026

Human DEAH-box helicase 8 regulates HSF1-mediated stress response and cancer-associated pre-mRNA splicing in tumour cells.

Jennifer R Tall, Robert Te Poele, Alexandra Vasile, Pradeep Ramagiri, James Campbell, Caitlin R Davies, Marissa V Powers, Toby Roe, Deivendran Sankaran, Hannah Wang and 6 more

Abstract read
In one paragraph

Article in NAR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jennifer R TallCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Robert Te PoeleCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Alexandra VasileCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Pradeep RamagiriCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
James CampbellCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Caitlin R DaviesCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Marissa V PowersCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Toby RoeCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Deivendran SankaranCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Hannah WangCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Konstantinos MitsopoulosCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Bissan Al-LazikaniCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.ORCID 0000-0003-3367-2519
Rob L M van MontfortCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.ORCID 0000-0002-5688-3450
Emmanuel de BillyCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.
Paul WorkmanCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.ORCID 0000-0003-1659-3034
Paul A ClarkeCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5GP, United Kingdom.ORCID 0000-0001-9342-1290

Funding

Cancer Research UK C2739/A22897Cancer Research UK C309/A11566
6 · The paper itself

Abstract

Transcription factor heat shock factor 1 (HSF1) orchestrates the cellular stress response, promoting malignant transformation, unchecked proliferation, and stress-resilient survival of tumour cells. We set out to discover potentially druggable regulators of HSF1 activation and identified DEAH-box RNA helicase 8 (DHX8). We investigated the role of DHX8 in regulating HSF1 within the broader context of DHX8 function in cancer cells. DHX8 silencing induces intron retention in

Indexed as

DEAD-box RNA HelicasesDNA-Binding ProteinsNeoplasmsRNA PrecursorsRNA SplicingStress, PhysiologicalTranscription FactorsApoptosisCell Line, TumorGene Expression Regulation, NeoplasticHeat Shock Transcription FactorsHumansIntronsRNA, MessengerDEAD-box RNA HelicasesDNA-Binding ProteinsHeat Shock Transcription FactorsHSF1 protein, humanRNA, MessengerRNA PrecursorsTranscription Factors

Identifiers

PMID41837178
PMCPMC12980071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.